Free prostate-specific antigen in serum is becoming more complex (Q34130219)

31 July 2017

1 reference

title

Free prostate-specific antigen in serum is becoming more complex (English)

1 reference

31 July 2017

3

Alan W Partin

1 reference

31 July 2017

Stephen D Mikolajczyk

series ordinal

1

1 reference

31 July 2017

Leonard S Marks

series ordinal

2

1 reference

31 July 2017

Harry G Rittenhouse

series ordinal

4

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

31 July 2017

1 reference

31 July 2017

59

1 reference

31 July 2017

6

1 reference

31 July 2017

797-802

1 reference

Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901605-3

7 January 2021

Epitope mapping and affinity estimation of 83 antibodies against prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901605-3

7 January 2021

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901605-3

7 January 2021

Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901605-3

7 January 2021

A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901605-3

7 January 2021

"BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901605-3

7 January 2021

Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901605-3

7 January 2021

Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901605-3

7 January 2021

Activation of prostate-specific antigen precursor (pro-PSA) by prostin, a novel human prostatic serine protease identified by degenerate PCR

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901605-3

7 January 2021

Molecular heterogeneity of free PSA in sera of patients with benign and malignant prostate tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901605-3

7 January 2021

Production and activation of recombinant hK2 with propeptide mutations resulting in high expression levels

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901605-3

7 January 2021

Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901605-3

7 January 2021

Seminal plasma contains "BPSA," a molecular form of prostate-specific antigen that is associated with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901605-3

7 January 2021

Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901605-3

7 January 2021

Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901605-3

7 January 2021

Different proportions of various prostate-specific antigen (PSA) and human kallikrein 2 (hK2) forms are present in noninduced and androgen-induced LNCaP cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901605-3

7 January 2021

Measurement of complexed PSA improves specificity for early detection of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901605-3

7 January 2021

Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901605-3

7 January 2021

A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901605-3

7 January 2021

Production of alpha-1-antichymotrypsin by PSA-containing cells of human prostate epithelium

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901605-3

7 January 2021

Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901605-3

7 January 2021

Serum percent free prostate-specific antigen in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901605-3

7 January 2021

Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901605-3

7 January 2021

Prostate-specific antigen density: correlation with histological diagnosis of prostate cancer, benign prostatic hyperplasia and prostatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901605-3

7 January 2021

10.1016/S0090-4295(01)01605-3

Identifiers

DOI

1 reference

31 July 2017

1 reference